These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 20014314)

  • 21. Validation of the diagnostic value of NMP22 BladderChek test as a marker for bladder cancer by photodynamic diagnosis.
    Tritschler S; Scharf S; Karl A; Tilki D; Knuechel R; Hartmann A; Stief CG; Zaak D
    Eur Urol; 2007 Feb; 51(2):403-7; discussion 407-8. PubMed ID: 16939699
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Evaluation of urinary NMP22 (nuclear matrix protein 22) as a diagnostic marker for urothelial cancer--NMP22 as a urinary marker for surveillance of bladder cancer. NMP22 Study Group].
    Akaza H; Miyanaga N; Tsukamoto T; Ishikawa S; Noguchi R; Ohtani M; Kawabe K; Kubota Y; Fujita K; Obata K; Hirao Y; Kotake T; Ohmori H; Kumazawa J; Koiso K
    Gan To Kagaku Ryoho; 1997 May; 24(7):829-36. PubMed ID: 9170521
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cytologic diagnosis of low-grade papillary urothelial neoplasms (low malignant potential and low-grade carcinoma) in the context of the 1998 WHO/ISUP classification.
    Whisnant RE; Bastacky SI; Ohori NP
    Diagn Cytopathol; 2003 Apr; 28(4):186-90. PubMed ID: 12672093
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic value of cytology, nuclear matrix protein 22 (NMP22) test, and urinary bladder cancer II (UBC II) test in early recurrent transitional cell carcinoma of the bladder.
    Kibar Y; Goktas S; Kilic S; Yaman H; Onguru O; Peker AF
    Ann Clin Lab Sci; 2006; 36(1):31-8. PubMed ID: 16501234
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Expression and clinical significance of nuclear matrix protein 22 and cytokeratin 18 in transitional cell carcinoma of the bladder].
    Song JW; DU LL; Zhao XW; Jing JX; Han CZ; Cui Y; Liu JW; Hao HL; Wang ZG; Mi ZG
    Zhonghua Zhong Liu Za Zhi; 2009 Apr; 31(4):274-7. PubMed ID: 19615282
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Detection of recurrent bladder cancer: NMP22 test or urine cytology?
    Hosseini J; Golshan AR; Mazloomfard MM; Mehrsai AR; Zargar MA; Ayati M; Shakeri S; Jasemi M; Kabiri M
    Urol J; 2012; 9(1):367-72. PubMed ID: 22395834
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Variability in the performance of nuclear matrix protein 22 for the detection of bladder cancer.
    Shariat SF; Marberger MJ; Lotan Y; Sanchez-Carbayo M; Zippe C; Lüdecke G; Boman H; Sawczuk I; Friedrich MG; Casella R; Mian C; Eissa S; Akaza H; Serretta V; Huland H; Hedelin H; Raina R; Miyanaga N; Sagalowsky AI; Roehrborn CG; Karakiewicz PI
    J Urol; 2006 Sep; 176(3):919-26; discussion 926. PubMed ID: 16890655
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cytokeratin-20 immunocytochemistry in voided urine cytology and its comparison with nuclear matrix protein-22 and urine cytology in the detection of urothelial carcinoma.
    Srivastava R; Arora VK; Aggarwal S; Bhatia A; Singh N; Agrawal V
    Diagn Cytopathol; 2012 Sep; 40(9):755-9. PubMed ID: 22888081
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Value of p16(INK4a) in the diagnosis of low-grade urothelial carcinoma of the urinary bladder in urinary cytology.
    Alameda F; Juanpere N; Pijuan L; Lloveras B; Gimeno J; Baró T; Salido M; Serrano S; Lloreta J
    Cancer Cytopathol; 2012 Aug; 120(4):276-82. PubMed ID: 22419364
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of the sensitivity and specificity of urine cytology, urinary nuclear matrix protein-22 and multitarget fluorescence in situ hybridization assay in the detection of bladder cancer.
    Kehinde EO; Al-Mulla F; Kapila K; Anim JT
    Scand J Urol Nephrol; 2011 Mar; 45(2):113-21. PubMed ID: 21091091
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunocyt test improves the diagnostic accuracy of urinary cytology: results of a French multicenter study.
    Pfister C; Chautard D; Devonec M; Perrin P; Chopin D; Rischmann P; Bouchot O; Beurton D; Coulange C; Rambeaud JJ
    J Urol; 2003 Mar; 169(3):921-4. PubMed ID: 12576813
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of different grades of microscopic hematuria on the performance of urine-based markers for the detection of urothelial carcinoma.
    Todenhöfer T; Hennenlotter J; Tews V; Gakis G; Aufderklamm S; Kuehs U; Stenzl A; Schwentner C
    Urol Oncol; 2013 Oct; 31(7):1148-54. PubMed ID: 22130125
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Urinary levels of tumor-associated trypsin inhibitor (TATI) in the detection of transitional cell carcinoma of the urinary bladder.
    Shariat SF; Herman MP; Casella R; Lotan Y; Karam JA; Stenman UH
    Eur Urol; 2005 Sep; 48(3):424-31. PubMed ID: 15963628
    [TBL] [Abstract][Full Text] [Related]  

  • 34. NMP22 is a sensitive, cost-effective test in patients at risk for bladder cancer.
    Zippe C; Pandrangi L; Agarwal A
    J Urol; 1999 Jan; 161(1):62-5. PubMed ID: 10037369
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combinations of urine-based tumour markers in bladder cancer surveillance.
    Horstmann M; Patschan O; Hennenlotter J; Senger E; Feil G; Stenzl A
    Scand J Urol Nephrol; 2009; 43(6):461-6. PubMed ID: 19903092
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combined application of cytology and molecular urine markers to improve the detection of urothelial carcinoma.
    Todenhöfer T; Hennenlotter J; Esser M; Mohrhardt S; Tews V; Aufderklamm S; Gakis G; Kuehs U; Stenzl A; Schwentner C
    Cancer Cytopathol; 2013 May; 121(5):252-60. PubMed ID: 23172833
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Screening and monitoring for bladder cancer: refining the use of NMP22.
    Ponsky LE; Sharma S; Pandrangi L; Kedia S; Nelson D; Agarwal A; Zippe CD
    J Urol; 2001 Jul; 166(1):75-8. PubMed ID: 11435827
    [TBL] [Abstract][Full Text] [Related]  

  • 38. NMP22: a sensitive, cost-effective test in patients at risk for bladder cancer.
    Zippe C; Pandrangi L; Potts JM; Kursh E; Novick A; Agarwal A
    Anticancer Res; 1999; 19(4A):2621-3. PubMed ID: 10470205
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Four bladder tumor markers have a disappointingly low sensitivity for small size and low grade recurrence.
    Boman H; Hedelin H; Holmäng S
    J Urol; 2002 Jan; 167(1):80-3. PubMed ID: 11743280
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Analysis of fluorescence in situ hybridization, mtDNA quantification, and mtDNA sequence for the detection of early bladder cancer.
    Yoo JH; Suh B; Park TS; Shin MG; Choi YD; Lee CH; Choi JR
    Cancer Genet Cytogenet; 2010 Apr; 198(2):107-17. PubMed ID: 20362225
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.